$CRIS
CURIS INC Stock $cris

$cris Overview Financials Valuation SEC Filings Company Website

2022 Q3 Form 10-Q Financial Statement

#000110820522000009 Filed on August 04, 2022

Income Statement

Concept	2022 Q3	2022 Q2	2022 Q1
Revenue	$2.825M	$2.393M	$2.057M
YoY Change	-7.04%	4.68%	-6.03%
Cost Of Revenue	$62.00K	$42.00K	$82.00K
YoY Change	-58.94%	-63.79%	-25.45%
Gross Profit	$2.763M	$2.351M	$1.975M
YoY Change	-4.33%	8.34%	-5.05%
Gross Profit Margin	97.81%	98.24%	96.01%
Selling, General & Admin	$4.556M	$5.089M	$5.673M
YoY Change	5.12%	25.13%	37.69%
% of Gross Profit	164.89%	216.46%	287.24%
Research & Development	$10.81M	$12.32M	$11.44M
YoY Change	25.7%	40.79%	69.23%
% of Gross Profit	391.35%	524.16%	578.99%
Depreciation & Amortization	$61.00K	$44.00K	$36.00K
YoY Change	69.44%	0.0%	-10.0%
% of Gross Profit	2.21%	1.87%	1.82%
Operating Expenses	$10.81M	$12.32M	$11.44M
YoY Change	25.7%	40.79%	69.23%
Operating Profit	-$12.61M	-$15.06M	-$15.13M
YoY Change	25.46%	41.42%	71.97%
Interest Expense	$335.0K	$162.0K	$80.00K
YoY Change	520.37%	179.31%	60.0%
% of Operating Profit
Other Income/Expense, Net	-$688.0K	-$879.0K	-$976.0K
YoY Change	-31.41%	367.55%	-13.4%
Pretax Income	-$13.29M	-$15.94M	-$16.11M
YoY Change	20.3%	47.08%	62.23%
Income Tax
% Of Pretax Income
Net Earnings	-$13.29M	-$15.94M	-$16.11M
YoY Change	20.3%	47.08%	62.27%
Net Earnings / Revenue	-470.58%	-666.11%	-783.13%
Basic Earnings Per Share	-$0.14	-$0.17	-$0.18
Diluted Earnings Per Share	-$0.14	-$0.17	-$0.18
COMMON SHARES
Basic Shares Outstanding	91.81M shares	91.65M shares	91.65M shares
Diluted Shares Outstanding	93.79M shares	91.65M shares	91.65M shares

Balance Sheet

Concept	2022 Q3	2022 Q2	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$98.69M	$107.2M	$120.7M
YoY Change	-23.44%	-29.74%	-22.86%
Cash & Equivalents	$29.85M	$34.01M	$18.47M
Short-Term Investments	$68.84M	$73.19M	$102.2M
Other Short-Term Assets	$4.142M	$3.801M	$3.426M
YoY Change	34.13%	140.11%	3.82%
Inventory
Prepaid Expenses
Receivables	$2.886M	$2.395M	$2.060M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$105.7M	$113.4M	$126.1M
YoY Change	-21.66%	-27.56%	-22.07%
LONG-TERM ASSETS
Property, Plant & Equipment	$780.0K	$789.0K	$479.0K
YoY Change	43.65%	36.03%	-22.74%
Goodwill	$8.982M	$8.982M	$8.982M
YoY Change	0.0%	0.0%	0.0%
Intangibles
YoY Change
Long-Term Investments	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Other Assets	$2.022M	$635.0K	$726.0K
YoY Change
Total Long-Term Assets	$17.14M	$15.44M	$14.60M
YoY Change	-53.85%	-37.4%	-49.18%
TOTAL ASSETS
Total Short-Term Assets	$105.7M	$113.4M	$126.1M
Total Long-Term Assets	$17.14M	$15.44M	$14.60M
Total Assets	$122.9M	$128.8M	$140.7M
YoY Change	-28.61%	-28.9%	-26.16%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.756M	$5.511M	$4.281M
YoY Change	64.18%	36.04%	24.85%
Accrued Expenses	$6.883M	$5.575M	$4.586M
YoY Change	29.62%	75.15%	122.41%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$13.74M	$12.15M	$9.691M
YoY Change	45.06%	54.47%	38.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$53.37M	$54.64M	$55.07M
YoY Change	-10.61%	-10.21%	-10.74%
Total Long-Term Liabilities	$53.37M	$54.64M	$55.07M
YoY Change
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.74M	$12.15M	$9.691M
Total Long-Term Liabilities	$53.37M	$54.64M	$55.07M
Total Liabilities	$67.11M	$66.79M	$64.77M
YoY Change	-2.99%	-2.81%	-5.7%
SHAREHOLDERS EQUITY
Retained Earnings	-$1.100B	-$1.100B	-$1.100B
YoY Change	0.0%	0.0%	0.0%
Common Stock	$1.194B	$1.187B	$1.185B
YoY Change	1.04%	0.58%	0.52%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$55.75M	$62.05M	$75.97M
YoY Change
Total Liabilities & Shareholders Equity	$122.9M	$128.8M	$140.7M
YoY Change	-28.61%	-28.9%	-26.16%

Cashflow Statement

Concept	2022 Q3	2022 Q2	2022 Q1
OPERATING ACTIVITIES
Net Income	-$13.29M	-$15.94M	-$16.11M
YoY Change	20.3%	47.08%	62.27%
Depreciation, Depletion And Amortization	$61.00K	$44.00K	$36.00K
YoY Change	69.44%	0.0%	-10.0%
Cash From Operating Activities	-$13.12M	-$12.13M	-$16.80M
YoY Change	36.55%	82.22%	27.48%
INVESTING ACTIVITIES
Capital Expenditures	-$52.00K	-$353.0K	$11.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities	$4.355M	$28.69M	-$3.072M
YoY Change	-137.77%	-199.73%	-24.52%
Cash From Investing Activities	$4.303M	$28.34M	-$3.083M
YoY Change	-137.32%	-198.5%	-24.27%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	4.662M	-759.0K	-$1.648M
YoY Change	-587.66%	32.23%	24.0%
NET CHANGE
Cash From Operating Activities	-13.12M	-12.13M	-$16.80M
Cash From Investing Activities	4.303M	28.34M	-$3.083M
Cash From Financing Activities	4.662M	-759.0K	-$1.648M
Net Change In Cash	-4.157M	15.45M	-$21.55M
YoY Change	-81.19%	-142.91%	15.97%
FREE CASH FLOW
Cash From Operating Activities	-$13.12M	-$12.13M	-$16.80M
Capital Expenditures	-$52.00K	-$353.0K	$11.00K
Free Cash Flow	-$13.07M	-$11.78M	-$16.81M
YoY Change	36.0%	76.91%	27.56%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Amendment Flag AmendmentFlag	false
	dei	Document Quarterly Report DocumentQuarterlyReport	true
	dei	Document Period End Date DocumentPeriodEndDate	2022-06-30
	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02421
	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q2
	dei	Entity Central Index Key EntityCentralIndexKey	0001108205
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
	dei	Document Type DocumentType	10-Q
	dei	Document Transition Report DocumentTransitionReport	false
	dei	Entity File Number EntityFileNumber	000-30347
	dei	Entity Registrant Name EntityRegistrantName	CURIS, INC.
	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	04-3505116
	dei	Entity Address Address Line1 EntityAddressAddressLine1	128 Spring Street
	dei	Entity Address Address Line2 EntityAddressAddressLine2	Building C - Suite 500
	dei	Entity Address City Or Town EntityAddressCityOrTown	Lexington
	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
	dei	Security Exchange Name SecurityExchangeName	NASDAQ
	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
	dei	City Area Code CityAreaCode	617
	dei	Local Phone Number LocalPhoneNumber	503-6500
	dei	Security12b Title Security12bTitle	Common Stock, Par Value $0.01 per share
	dei	Trading Symbol TradingSymbol	CRIS
	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
	dei	Entity Small Business EntitySmallBusiness	false
	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
	dei	Entity Shell Company EntityShellCompany	false
CY2022Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	91814665	shares
CY2022Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	34008000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	40014000	usd
CY2022Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	73192000	usd
CY2021Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	75870000	usd
CY2022Q2	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2395000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3224000	usd
CY2022Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3801000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3267000	usd
CY2022Q2	us-gaap	Assets Current AssetsCurrent	113396000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	122375000	usd
CY2022Q2	us-gaap	Long Term Investments LongTermInvestments	0	usd
CY2021Q4	us-gaap	Long Term Investments LongTermInvestments	23964000	usd
CY2022Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	789000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	505000	usd
CY2022Q2	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	635000	usd
CY2021Q4	us-gaap	Restricted Cash Noncurrent RestrictedCashNoncurrent	726000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5032000	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5749000	usd
CY2022Q2	us-gaap	Goodwill Goodwill	8982000	usd
CY2021Q4	us-gaap	Goodwill Goodwill	8982000	usd
CY2022Q2	us-gaap	Assets Assets	128834000	usd
CY2021Q4	us-gaap	Assets Assets	162301000	usd
CY2022Q2	us-gaap	Accounts Payable Current AccountsPayableCurrent	5511000	usd
CY2021Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6417000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5575000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2022Q2	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	1065000	usd
CY2021Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	682000	usd
CY2022Q2	us-gaap	Liabilities Current LiabilitiesCurrent	12151000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13438000	usd
CY2022Q2	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3390000	usd
CY2021Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	4358000	usd
CY2022Q2	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	51248000	usd
CY2021Q4	cris	Royalty Guarantees Commitments Amount Noncurrent RoyaltyGuaranteesCommitmentsAmountNoncurrent	53798000	usd
CY2022Q2	us-gaap	Liabilities Liabilities	66789000	usd
CY2021Q4	us-gaap	Liabilities Liabilities	71594000	usd
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2022Q2	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91814665	shares
CY2022Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91814665	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
CY2021Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	91645369	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	91645369	shares
CY2022Q2	us-gaap	Common Stock Value CommonStockValue	918000	usd
CY2021Q4	us-gaap	Common Stock Value CommonStockValue	916000	usd
CY2022Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1186056000	usd
CY2021Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	1182225000	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1124374000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1092325000	usd
CY2022Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-555000	usd
CY2021Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-109000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	62045000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	usd
CY2022Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	128834000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	162301000	usd
CY2022Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2393000	usd
CY2021Q2	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	2286000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4450000	usd
	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4475000	usd
CY2022Q2	us-gaap	Royalty Expense RoyaltyExpense	42000	usd
CY2021Q2	us-gaap	Royalty Expense RoyaltyExpense	116000	usd
	us-gaap	Royalty Expense RoyaltyExpense	124000	usd
	us-gaap	Royalty Expense RoyaltyExpense	225000	usd
CY2022Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	12323000	usd
CY2021Q2	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	8753000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	23758000	usd
	us-gaap	Research And Development Expense Excluding Acquired In Process Cost ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost	15510000	usd
CY2022Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5089000	usd
CY2021Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	4067000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10762000	usd
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8190000	usd
CY2022Q2	us-gaap	Costs And Expenses CostsAndExpenses	17454000	usd
CY2021Q2	us-gaap	Costs And Expenses CostsAndExpenses	12936000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	34644000	usd
	us-gaap	Costs And Expenses CostsAndExpenses	23925000	usd
CY2022Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-15061000	usd
CY2021Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-10650000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-30194000	usd
	us-gaap	Operating Income Loss OperatingIncomeLoss	-19450000	usd
CY2022Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	162000	usd
CY2021Q2	us-gaap	Investment Income Interest InvestmentIncomeInterest	58000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	242000	usd
	us-gaap	Investment Income Interest InvestmentIncomeInterest	104000	usd
CY2022Q2	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1041000	usd
CY2021Q2	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	1136000	usd
	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	2097000	usd
	cris	Non Cash Imputed Interest Expense NonCashImputedInterestExpense	2309000	usd
CY2022Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
CY2021Q2	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	890000	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	0	usd
	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	890000	usd
CY2022Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-879000	usd
CY2021Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-188000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1855000	usd
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-1315000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-15940000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10838000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32049000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20765000	usd
CY2022Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.17
CY2022Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.17
CY2021Q2	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.12
CY2021Q2	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.12
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.35
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.35
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.23
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.23
CY2022Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91650950	shares
CY2022Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91650950	shares
CY2021Q2	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91547390	shares
CY2021Q2	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91547390	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91648175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91648175	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	91527563	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	91527563	shares
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-15940000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10838000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32049000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20765000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-104000	usd
CY2021Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-446000	usd
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	0	usd
CY2022Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16044000	usd
CY2021Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-10832000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-32495000	usd
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-20765000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	90707000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1718000	usd
CY2022Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-342000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-16109000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	600000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	75974000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1966000	usd
CY2022Q2	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	149000	usd
CY2022Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-104000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	-15940000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	62045000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	130670000	usd
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1099000	usd
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	79000	usd
CY2021Q1	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	-6000	usd
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-9927000	usd
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	121915000	usd
CY2021Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	1275000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Employee Stock Ownership Plan StockIssuedDuringPeriodValueEmployeeStockOwnershipPlan	68000	usd
CY2021Q2	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	48000	usd
CY2021Q2	us-gaap	Marketable Securities Unrealized Gain Loss MarketableSecuritiesUnrealizedGainLoss	6000	usd
CY2021Q2	us-gaap	Net Income Loss NetIncomeLoss	-10838000	usd
CY2021Q2	us-gaap	Stockholders Equity StockholdersEquity	112474000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32049000	usd
	us-gaap	Net Income Loss NetIncomeLoss	-20765000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	80000	usd
	us-gaap	Depreciation And Amortization DepreciationAndAmortization	84000	usd
	cris	Non Cash Lease Expense NonCashLeaseExpense	529000	usd
	cris	Non Cash Lease Expense NonCashLeaseExpense	407000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	3684000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	2374000	usd
	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	6000	usd
	cris	Non Cash Imputed Interest Expense Net Of Imputed Interest NonCashImputedInterestExpenseNetOfImputedInterest	3000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-575000	usd
	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-634000	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0	usd
	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	890000	usd
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-829000	usd
	us-gaap	Nature Of Operations NatureOfOperations	Nature of Business<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Curis, Inc. is a biotechnology company focused on the development of first-in-class and innovative therapeutics for the treatment of cancer. Throughout these Condensed Consolidated Financial Statements, Curis, Inc. and its wholly owned subsidiaries are collectively referred to as “the Company” or “Curis.”</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company conducts its research and development programs both internally and through strategic collaborations. The Company’s clinical stage drug candidates include emavusertib, previously CA-4948, an orally available small molecule inhibitor of Interleukin-1 receptor associated kinase 4 (“IRAK4”); CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation (“VISTA”) signaling pathway; fimepinostat, a small molecule that potently inhibits the activity of histone deacetylase and phosphotidyl-inositol 3 kinase enzymes; and CA-170, a small molecule antagonist of VISTA and PDL1. The Company's pre-clinical development candidates include CA-327, an orally available small molecule antagonist of PDL1 and TIM3.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is party to a collaboration with Genentech Inc. (“Genentech”), a member of the Roche Group, under which Genentech and F. Hoffmann-La Roche Ltd (“Roche”) are commercializing Erivedge® (vismodegib), a first-in-class orally administered small molecule Hedgehog signaling pathway antagonist. Erivedge is approved for the treatment of advanced basal cell carcinoma (“BCC”).</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In January 2015, the Company entered into an exclusive collaboration agreement with Aurigene Discovery Technologies Limited (“Aurigene”) for the discovery, development and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology, which was amended in September 2016 and February 2020. </span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Company is a party to an option and license agreement with ImmuNext. Pursuant to the terms of the option and license agreement, the Company has an option, exercisable for a specified period as set forth in the option and license agreement, to obtain an exclusive license to develop and commercialize certain VISTA antagonizing compounds, including ImmuNext's lead compound, CI-8993, and products containing these compounds in the field of oncology.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The COVID-19 pandemic has had and may continue to have an adverse effect on the Company’s business, financial condition, results of operations, and prospects. With respect to ongoing clinical trials, the anticipated timing of enrollment and the overall timelines of the trials have experienced delays and could be further delayed to the extent the Company experiences further delays in enrollment due to the COVID-19 pandemic. The Company’s ability to collect patient data in a timely fashion may also be impacted. The Company also experienced delays in closing down its clinical trial sites related to its fimepinostat and CA-170 trials due to restrictions on non-essential workers imposed at those sites in response to COVID-19, which delayed the winding down of these trials. In addition, the Company and its collaborators, third-party contract manufacturers, contract research organizations and clinical sites could experience delays or disruptions in supply and release of product candidates and/or procuring items that are essential for its research and development activities, including, for example, raw materials used in the manufacturing of its product candidates, basic medical and laboratory supplies used in its clinical trials or preclinical studies, or animals that are used for preclinical testing, in each case, for which there may be shortages or supply chain disruptions as a result of the continuing pandemic. The Company cannot be certain what the overall impact of the COVID-19 pandemic will be on its business.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks common to companies in the biotechnology industry as well as risks that are specific to the Company’s business, including, but not limited to: the Company’s ability to obtain adequate financing to fund its operations; the Company’s ability to advance and expand its research and development programs; the impacts of the COVID-19 pandemic and responsive actions related thereto; the Company’s reliance on Roche and Genentech to successfully commercialize Erivedge in the approved indication of advanced BCC and to progress its clinical development in indications other than BCC; the ability of the Company and its wholly owned subsidiary, Curis Royalty, LLC (“Curis Royalty”) to satisfy the terms of the royalty interest purchase agreement (the “Oberland Purchase Agreement”) with TPC Investments I LP and TPC Investments II LP ("the Purchasers"), each of which is a Delaware limited partnership managed by Oberland Capital Management, LLC, and Lind SA LLC ("the Agent"), a Delaware limited liability company managed by Oberland Capital Management, LLC, as collateral agent for the Purchasers; the Company’s ability to obtain and maintain necessary intellectual property protection; development by the Company’s competitors of new or better technological innovations; the Company’s ability to comply with regulatory requirements; the Company's ability to obtain and maintain applicable regulatory approvals and commercialize any approved product candidates; and the Company’s ability to execute on its overall business strategies.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s future operating results will largely depend on the progress of drug candidates currently in its development pipeline and the magnitude of payments that it may receive and make under its current and potential future collaborations. The results of the Company’s operations have varied and will likely continue to vary significantly from year to year and quarter to quarter and depend on a number of factors, including, but not limited to the timing, outcome and cost of the Company’s preclinical studies and clinical trials for its drug candidates.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will require substantial funds to maintain research and development programs and support operations. The Company has incurred net losses and negative cash flows from operations since its inception. As of June 30, 2022, the Company had an accumulated deficit of $1.1 billion, and for the six months ended June 30, 2022, the Company incurred a net loss of $32.0 million and used $28.9 million of cash in operations. The Company expects to continue to generate operating losses in the foreseeable future. The Company anticipates that its $107.2 million of existing cash, cash equivalents and investments at June 30, 2022 will be sufficient to fund operations for at least 12 months from the date of filing this Quarterly Report on Form 10-Q.</span></div><div style="margin-top:9pt;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company’s ability to raise additional funds will depend, among other factors, on financial, economic and market conditions, many of which are outside of its control and it may be unable to raise financing when needed, or on terms favorable to the Company. If necessary funds are not available, the Company will have to delay, reduce the scope of, or eliminate some of its development programs, potentially delaying the time to market for or preventing the marketing of any of its product candidates.</span></div>
	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-664000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	536000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	366000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-1671000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-557000	usd
	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-394000	usd
	cris	Increase Decrease Operating Lease Liability IncreaseDecreaseOperatingLeaseLiability	-1426000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	3102000	usd
	us-gaap	Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivities	927000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28947000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-19838000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	35774000	usd
	us-gaap	Payments To Acquire Investments PaymentsToAcquireInvestments	54947000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	61395000	usd
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	22105000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	364000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	0	usd
CY2022Q2	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-1100000000	usd
CY2021Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	25257000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-32842000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	149000	usd
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlans	195000	usd
	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	2556000	usd
	cris	Payments Of Future Royalty Liability Net Of Imputed Interest PaymentsOfFutureRoyaltyLiabilityNetOfImputedInterest	2099000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-2407000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1904000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-6097000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-54584000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	40740000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	130426000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34643000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75842000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2091000	usd
	us-gaap	Interest Paid Net InterestPaidNet	2305000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	1700000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-191000	usd
	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	0	usd
	us-gaap	Net Income Loss NetIncomeLoss	-32000000.0	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-28900000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	107200000	usd
	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates and Assumptions<div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company’s Condensed Consolidated Financial Statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts and disclosure of certain assets and liabilities at the balance sheet date. Such estimates include the performance obligations under the Company’s collaboration agreements; the estimated repayment term of the Company’s debt and related short- and long-term classification; the collectability of receivables; the carrying value of property and equipment and goodwill; and the assumptions used in the Company’s valuation of stock-based compensation and the value of certain investments and liabilities. Actual results may differ from such estimates.</span></div><div style="margin-top:6pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These interim results are not necessarily indicative of results to be expected for a full year or subsequent interim periods.</span></div><div style="margin-top:9pt;text-indent:22.5pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The extent to which COVID-19 has had and may continue to have impacts on the Company’s business and financial results will depend on numerous evolving factors including, but not limited to: the magnitude and duration of the continuing COVID-19 pandemic, the extent to which it has impacted and may continue to impact worldwide macroeconomic conditions including interest rates, employment rates and health insurance coverage, the speed of the anticipated recovery, and governmental and business responses to the pandemic. The Company assessed certain accounting matters that generally require consideration of forecasted financial information in context with the information reasonably available to the Company and the unknown future impacts of COVID-19 as of June 30, 2022 and through the date of this report. The Company’s future assessment of the magnitude and duration of the COVID-19 pandemic, as well as other factors, could result in material impacts to the Company’s consolidated financial statements in future reporting periods.</span></div>
CY2022Q2	us-gaap	Restricted Cash RestrictedCash	600000	usd
CY2021Q4	us-gaap	Restricted Cash RestrictedCash	700000	usd
CY2022Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	34600000	usd
CY2021Q2	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	75800000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	73747000	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2022Q2	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	555000	usd
CY2022Q2	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	73192000	usd
	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y6M
CY2021Q4	us-gaap	Available For Sale Debt Securities Amortized Cost Basis AvailableForSaleDebtSecuritiesAmortizedCostBasis	99943000	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	0	usd
CY2021Q4	us-gaap	Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	109000	usd
CY2021Q4	us-gaap	Available For Sale Securities Debt Securities AvailableForSaleSecuritiesDebtSecurities	99834000	usd
CY2021	cris	Available For Sale Securities Weighted Average Maturity AvailableForSaleSecuritiesWeightedAverageMaturity	P0Y4M24D
CY2021Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Debt Securities Available For Sale Allowance For Credit Loss DebtSecuritiesAvailableForSaleAllowanceForCreditLoss	0	usd
CY2022Q2	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	2708000	usd
CY2021Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	3260000	usd
CY2022Q2	cris	Chemistry Manufacturing And Controls Costs ChemistryManufacturingAndControlsCosts	1515000	usd
CY2021Q4	cris	Chemistry Manufacturing And Controls Costs ChemistryManufacturingAndControlsCosts	2232000	usd
CY2022Q2	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	828000	usd
CY2021Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	644000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	524000	usd
CY2021Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	203000	usd
CY2022Q2	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	5575000	usd
CY2021Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	6339000	usd
CY2020Q2	us-gaap	Long Term Debt LongTermDebt	900000	usd
CY2022Q2	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0995
CY2022Q1	cris	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	-1100000	usd
CY2022Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-1100000	usd
CY2022Q2	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	900000	usd
CY2022Q2	cris	Increase Decrease In Operating Lease Right Of Use Asset IncreaseDecreaseInOperatingLeaseRightOfUseAsset	900000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	4500000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5000000.0	usd
CY2021Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	5000000.0	usd
CY2021Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	5700000	usd
CY2022Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	400000	usd
CY2021Q2	us-gaap	Operating Lease Expense OperatingLeaseExpense	300000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	700000	usd
CY2022Q2	us-gaap	Lessee Operating Lease Remaining Lease Term LesseeOperatingLeaseRemainingLeaseTerm	P6Y
CY2022Q2	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	8800000	usd
CY2022Q2	us-gaap	Operating Lease Payments OperatingLeasePayments	300000	usd
	cris	Operating Lease One Time Payment Tenant Improvements OperatingLeaseOneTimePaymentTenantImprovements	1100000	usd
CY2021Q2	cris	Operating Lease One Time Payment Tenant Improvements OperatingLeaseOneTimePaymentTenantImprovements	1100000	usd
CY2019Q1	cris	Royalty Purchase Agreement Interest Rate RoyaltyPurchaseAgreementInterestRate	0.079
CY2019Q1	cris	Royalty Purchase Agreement Transaction Fees And Closing Costs RoyaltyPurchaseAgreementTransactionFeesAndClosingCosts	600000	usd
CY2021Q4	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	53798000	usd
	cris	Royalty Purchase Agreement Issuance Costs Capitalized Amortization RoyaltyPurchaseAgreementIssuanceCostsCapitalizedAmortization	31000	usd
	cris	Royalty Purchase Agreement Accretion Expense RoyaltyPurchaseAgreementAccretionExpense	2065000	usd
	cris	Payments Of Future Royalty Liability PaymentsOfFutureRoyaltyLiability	4646000	usd
CY2022Q2	cris	Royalty Purchase Agreement Liability Carrying Value RoyaltyPurchaseAgreementLiabilityCarryingValue	51248000	usd
	cris	Collaboration Agreement Numberof Programs Licensed CollaborationAgreementNumberofProgramsLicensed	4	program
CY2021Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	151875000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	227812500	shares
	cris	Share Based Compensation Plans ShareBasedCompensationPlans	2	plan
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	10363769	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.80
CY2021	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y4M28D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	4694350	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	3.14
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	472820	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	7.29
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	14585299	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.47
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P7Y8M23D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	19000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	7398636	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	3.32
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y6M18D
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	11000	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	13783730	shares
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	3.46
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P7Y7M20D
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue	18000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	2.57
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	9.42
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y6M
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.025
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum	0.004
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum	0.014
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Minimum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum	1.10
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate Maximum ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum	1.12
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.07
CY2022Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	16300000	usd
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y7M20D
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Nonvested Number ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber	0	shares
CY2022Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1966000000	usd
CY2021Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	1275000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	3684000000	usd
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2374000	usd

Files In Submission

Name	View Source	Status
0001108205-22-000009-index-headers.html	Edgar Link	pending
0001108205-22-000009-index.html	Edgar Link	pending
0001108205-22-000009.txt	Edgar Link	pending
0001108205-22-000009-xbrl.zip	Edgar Link	pending
a_exx101xsteinkraussconsul.htm	Edgar Link	pending
cris-20220630.htm	Edgar Link	pending
cris-20220630.xsd	Edgar Link	pending
cris-20220630_cal.xml	Edgar Link	unprocessable
cris-20220630_def.xml	Edgar Link	unprocessable
cris-20220630_htm.xml	Edgar Link	completed
cris-20220630_lab.xml	Edgar Link	unprocessable
cris-20220630_pre.xml	Edgar Link	unprocessable
cris-6302022x10qexx311.htm	Edgar Link	pending
cris-6302022x10qexx312.htm	Edgar Link	pending
cris-6302022x10qexx321.htm	Edgar Link	pending
cris-6302022x10qexx322.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CRIS
CURIS INC Stock $cris

2022 Q3 Form 10-Q Financial Statement

#000110820522000009 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS CURIS INC Stock $cris

2022 Q3 Form 10-Q Financial Statement

#000110820522000009 Filed on August 04, 2022

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CRIS
CURIS INC Stock $cris